# RVAC Medicines Pte.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rvac-medicines-pte

- Industry: Biotechnology
- Headquarters: Singapore
- Website: www.rvacmed.com
- Total disclosed funding: $140M
- Latest round: Series B (Apr 26, 2022)
- Investors on record: 4

## About

Based in Singapore, and founded in 2021 by its CEO Sean Fu, and CSO Jason Zhang, RVAC Medicines Pte. Ltd. operates as a messenger (mRNA) ribonucleic acid platform company. In April 2022, RVAC Medicines Pte. Ltd. raised USD 140 million in series B funding led by new investor CBC Group, with participation from other new investors EDBI, GS Holdings, and Pavilion Capital.

RVAC Medicines provides GMP manufacturing capabilities; MSAT infrastructure for process scale-up and tech transfer; develops single and multi-mRNA/DNA products, etc.

The company plans to use the April 2022 funding to accelerate the development of a multivalent COVID vaccine.

## Funding rounds

- Series B, Apr 26, 2022, $140M — SG Growth Capital, Pavilion Capital, CBC Group, GS Holdings

## Investors

- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series B
- Pavilion Capital — Series B
- CBC Group (https://capitalatlas.ai/funds/cbc-group) — Series B
- GS Holdings — Series B